ASNA and Athinia® collaborate to boost semiconductor manufacturing yields through improved data sharing and traceability of subcomponent parts
CAMBRIDGE, Mass., July 8, 2024 /PRNewswire/ -- Today Athinia® announced a collaboration with ASNA to combine unprecedented data sharing and traceability to improve critical semiconductor component and subcomponent innovation. In today's fiercely competitive semiconductor landscape, the quality an...
Micron to Select Athinia™ for Pioneering Data Collaboration
A long-term, strategic, enterprise-level technology collaboration aims to further increase production efficiencies and reduce costs for Micron and its suppliers CAMBRIDGE, Mass., July 19, 2022 /PRNewswire/ -- Today, Athinia™ announced that Micron Technology, Inc. (Nasdaq: MU), a global leader in...
ERBITUX® Approved for First-line Use in China in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
Approval is for ERBITUX® in combination with platinum-based therapy with fluorouracil for the first-line treatment of R/M SCCHN Pivotal Phase III study shows significant improvements with ERBITUX® in combination with platinum-based therapy with fluorouracil in response rate, disease progression ...
Merck Announces Orphan Drug Designation for Investigational Therapy Tepotinib in Patients with NSCLC Harboring MET Gene Alterations
- Japanese Ministry of Health, Labour and Welfare grants orphan drug designation for diseases that affect fewer than 50,000 patients inJapan, and for which significant unmet medical need exists - MET exon 14 (METex14) skipping alterations and MET amplifications are present in 3-5% of non-small c...
Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine
Not intended for US, Canada and UK-based media DARMSTADT, Germany and NEW YORK, Feb. 18, 2019 /PRNewswire/ -- * JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression * US FDA has granted Priority Rev...
